SHINING ELECTRIC
870299
HLHS
833455
LEETRO
430425
4
LIERDA
832149
5
Jiangsu Allfavor Intelligent Circuits Technology
300964
US Stock MarketDetailed Quotes
IONS Ionis Pharmaceuticals
- 32.950
- +0.350+1.07%
Close Mar 4 16:00 ET
- 32.600
- -0.350-1.06%
Post 18:33 ET
5.24BMarket Cap-10.84P/E (TTM)
33.560High31.990Low1.48MVolume32.420Open32.600Pre Close48.85MTurnover0.94%Turnover RatioLossP/E (Static)158.96MShares52.34052wk High8.90P/B5.19BFloat Cap30.23052wk Low--Dividend TTM157.59MShs Float86.582Historical High--Div YieldTTM4.82%Amplitude2.500Historical Low32.946Avg Price1Lot Size
Trending Stocks
Discussing
As China's 'two sessions' approach: How will Chinese stocks perform?
🎙️Discussion 1. With China's 'two sessions' approaching, do you focus more on policy dynamics or capital flows? 2. Which industry sectors d
Moomoo News Global
Feb 24 22:30
Chinese Stocks' Wild Rally Hits Pause? Wall Street Still Bets Big on Favorites
Ionis Pharmaceuticals Stock Forum
$Ionis Pharmaceuticals (IONS.US)$ : 🤔
⇨ IONIS-APOCIII-LRx (Olezarsen)
‣ FCS (Familial chylomicronemia syndrome)
‣ PDUFA: 12/19/24 (NDA)
🗓️ Last Week’s PDUFA Decisions:
$Checkpoint Therapeutics (CKPT.US)$ : Approved 12/13/24 ✅
⇨ UNLOXCYT (cosibelimab-ipdl)
‣ metastatic or locally advanced cSCC (cutaneous squamous cell carcinoma)
‣ PDUFA: 12/28/24 (resubmitted BLA)
$Neurocrine Biosciences (NBIX.US)$ : Approved 12/13/24 ✅
⇨ CRENESSITY™ (crin...
$Ionis Pharmaceuticals (IONS.US)$ ⇨ IONIS-APOCIII-LRx (Olezarsen)
$ZLDPF ⇨ Glepaglutide
$Rhythm Pharmaceuticals (RYTM.US)$ ⇨ IMCIVREE™ (Setmelanotide)
$Mirum Pharmaceuticals (MIRM.US)$ ⇨ Chenodal® (chenodiol)
$Checkpoint Therapeutics (CKPT.US)$ ⇨ Cosibelimab (CK-301)
$Neurocrine Biosciences (NBIX.US)$ ⇨ Crinecerfont capsule
$Bristol-Myers Squibb (BMY.US)$ ⇨ Opdivo® Subcutaneous (nivolumab + hyaluronidase)
$Neurocrine Biosciences (NBIX.US)$ ⇨ Crinecerfont oral solution
$BeiGene (BGNE.US)$ ⇨ Tisleli...
Has PDUFA coming up soon.
$Ionis Pharmaceuticals (IONS.US)$ ⇨ IONIS-APOCIII-LRx (Olezarsen)
$ZLDPF ⇨ Glepaglutide
$Rhythm Pharmaceuticals (RYTM.US)$ ⇨ IMCIVREE™ (Setmelanotide)
$Mirum Pharmaceuticals (MIRM.US)$ ⇨ Chenodal® (chenodiol)
$Checkpoint Therapeutics (CKPT.US)$ ⇨ Cosibelimab (CK-301)
$Neurocrine Biosciences (NBIX.US)$ ⇨ Crinecerfont capsule
$Bristol-Myers Squibb (BMY.US)$ ⇨ Opdivo® Subcutaneous (nivolumab + hyaluronidase)
$Neurocrine Biosciences (NBIX.US)$ ⇨ Crinece...
NEWS
“Ionis Pharmaceuticals announces positive Phase 3 results for olezarsen in treating familial chylomicronemia syndrome, showing significant reduction in triglycerides and acute pancreatitis events, potentially offering a breakthrough treatment option.
Results demonstrate olezarsen may represent a novel treatment option for this rare, life-threatening disease, for which there are no approved treatments in the U.S.”
No comment yet